New drug combo aims to unleash immune system on liver cancer
NCT ID NCT03680508
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether two immunotherapy drugs, cobolimab and dostarlimab, can help people with advanced liver cancer. The drugs work by helping the immune system recognize and attack cancer cells. The study involves 42 adults whose liver cancer has spread or cannot be removed by surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cobolimab and dostarlimab (immunotherapy drugs)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with advanced liver cancer that cannot be removed by surgery.
- What could go wrong
- This is a small, early-phase trial with only 42 participants, so results may not apply to everyone. Immunotherapy can cause serious side effects like inflammation in healthy organs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT PRIMARY LIVER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Oregon Health & Science University Knight Cancer Institute
Portland, Oregon, 97239, United States
-
University of Hawaii
Honolulu, Hawaii, 96813, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.